Tags: Glaxo | Novartis | cancer | immune

Glaxo's Adaptimmune Deal Shows Cancer Work Endures Novartis Swap

Monday, 02 Jun 2014 09:26 AM

GlaxoSmithKline Plc began a collaboration with Adaptimmune Ltd. to develop cancer medicines that would bolster a type of white blood cell key to the body’s own defense system.

Glaxo will pay more than $350 million over the next seven years if the collaboration is successful, closely held Adaptimmune, a biotechnology company based near Oxford, said in a statement today. The deal includes further payments later, including royalties, it said without elaborating.

The collaboration indicates the U.K.’s largest drugmaker remains interested in cancer research, even after agreeing to sell its oncology drugs to Novartis AG for as much as $16 billion in April. Glaxo will work with Adaptimmune’s cell-based approach as an alternative to immunotherapies targeting proteins called PD-1 and PD-L1, currently favored by drugmakers including Merck & Co., Bristol-Myers Squibb Co., AstraZeneca Plc and Roche Holding AG.

“This combination of capabilities offers an opportunity for significant progress in the use of the body’s immune system to fight cancer,” Axel Hoos, vice president of oncology R&D at Glaxo, said in the statement.

Glaxo doesn’t have any PD-1 programs of its own, spokesman David Daley said by telephone.

© Copyright 2017 Bloomberg News. All rights reserved.

 
1Like our page
2Share
Companies
GlaxoSmithKline Plc began a collaboration with Adaptimmune Ltd. to develop cancer medicines that would bolster a type of white blood cell key to the body's own defense system.
Glaxo, Novartis, cancer, immune
186
2014-26-02
Monday, 02 Jun 2014 09:26 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved